BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple ...
As online sales transactions increase in volume year after year, companies that provide tax automation are seeing a major increase in the need for their services. Vertex is one of those companies, and ...
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex (VRTX) to submit first module before end of year - - Second pivotal ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions ...
To receive Vertex and CRISPR Therapeutics’ $2.2 million gene therapy Casgevy for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), patients must first undergo chemotherapy to ...
Vertex has announced an online certification program through which continuing professional education credits can be earned. The program, Vertex Certified, uses a remote, Web-based learning format for ...
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication ...
The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results